Table 1.
Clinical and pathological characteristics of forty two LABC patients.
| Characteristics | Pathological responders (n = 24) (complete and partial) | Pathological Non-responders (n = 18) | Clinical responders (n = 26) | Clinical non-responders (n = 16) |
|---|---|---|---|---|
| Mean age (years) (range) | 44.7 ± 8.1 (34–65) | 43.4 ± 12.3 (19–65) | 42.9 ± 9.4 (19–65) | 46.3 ± 10.9 (28–65) |
| MENOPAUSAL STATUS | ||||
| Pre (n = 21) | 12 | 9 | 15 | 6 |
| Post (n = 21) | 12 | 9 | 11 | 10 |
| T STAGE | ||||
| T2 (n = 9) | 6 | 3 | 5 | 4 |
| T3 (n = 15) | 10 | 5 | 10 | 5 |
| T4 (n = 18) | 8 | 10 | 11 | 7 |
| ESTROGEN RECEPTOR | ||||
| Positive (n = 19) | 10 | 9 | 12 | 7 |
| Negative (n = 21) | 12 | 9 | 12 | 9 |
| NA (n = 2) | 2 | – | 2 | – |
| PROGESTERONE RECEPTOR | ||||
| Positive (n = 14) | 7 | 7 | 8 | 6 |
| Negative (n = 26) | 15 | 11 | 16 | 10 |
| NA (n = 2) | 2 | – | 2 | – |
| HER2 RECEPTOR | ||||
| 1+ (n = 18) | 8 | 10 | 9 | 9 |
| 2+ (n = 4) | 4 | – | 4 | – |
| 3+ (n = 18) | 10 | 8 | 11 | 7 |
| NA (n = 2) | 2 | – | 2 | – |
| CHEMOTHERAPY | ||||
| CAF (n = 7) | 4 | 3 | 6 | 1 |
| CEF (n = 21) | 13 | 8 | 9 | 12 |
| DE (n = 10) | 5 | 5 | 8 | 2 |
| Taxane (n = 1) | 1 | – | 1 | – |
| CEF+DE (n = 1) | 1 | – | 1 | – |
| DEC (n = 1) | – | 1 | – | 1 |
| DE+Herceptin (n = 1) | – | 1 | 1 | – |
| PLANNING AFTER III NACT | ||||
| MRM (n = 31) | 15 | 16 | 17 | 14 |
| BCS (n = 11) | 9 | 2 | 9 | 2 |
CAF, Cyclophosphamide Adriamycin 5-Fluorouracil (5FU); CEF, Cyclophosphamide Epirubicin and 5FU; DE, Docetaxel Epirubicin; DC, Docetaxel Cisplatin; DEC, Docetaxel Epirubicin Cisplatin; MRM, Modified Radical Mastectomy; BCS, Breast Conservation Surgery (includes wide local excision + axillary clearance); HER2, Human epidermal growth factor; NA, Not Available.